Physician profile
Kenneth Blank
NPI 1093739039
$1,570.38
in general payments reported to CMS, 2019-2025
26 companies · $552 in 2025
The $552 reported for 2025 was more than what 77% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.19 · 2020: $14.14 · 2022: $67.15 · 2023: $396 · 2024: $480 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $277.15 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $173.63 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $109.68 | 2023-2024 | Injectafer |
| Pfizer INC. | $108.12 | 2022-2025 | |
| Organon LLC | $93.81 | 2023-2024 | Nexplanon |
| Sage Therapeutics, LLC | $88.55 | 2025 | Zurzuvae |
| Viiv Healthcare Company | $82.76 | 2024-2025 | Apretude |
| Shield Therapeutics INC | $70.51 | 2025 | |
| Avion Pharmaceuticals | $61.70 | 2019-2020 | |
| Aspira Women'S Health INC | $60.71 | 2022-2024 | Ova1 |
| Millicent US INC | $57.57 | 2023-2024 | Intrarosa, Femring |
| Hologic Sales and Service, LLC | $49.71 | 2019-2023 | Aptima |
| Exact Sciences Corporation | $44.95 | 2023-2024 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $32.02 | 2023 | |
| Seqirus USA INC | $31.86 | 2025 | Fluad, Flucelvax |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $31.34 | 2025 | Qelbree |
| Abbvie INC. | $30.80 | 2025 | |
| Dexcom, INC. | $23.60 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $21.96 | 2024 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $21.90 | 2025 | Fruzaqla |
| Myovant Sciences INC. | $21.46 | 2022 | |
| Caris Mpi, INC. | $20.44 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $20.00 | 2023 | Gardasil 9, Pneumovax 23 |
| Blueprint Medicines Corporation | $18.92 | 2024 | Ayvakit |
| Optumhealth Care Solutions, LLC | $17.23 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.